New paradigms for Hsp90 inhibition
New paradigms for Hsp90 inhibition
批准号:
10000886
负责人:
Brian S J Blagg
金额:
$35.41万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-09-15 至 2021-11-30
关键词:
Amino AcidsAntineoplastic AgentsBindingBinding SitesCardiotoxicityCell ProliferationClientClinical TrialsComplexCrystallizationDataDevelopmentDiseaseDoseDrug DesignEvaluationExhibitsFrequenciesGenerationsHSP 90 inhibitionHeat shock proteinsHeat-Shock ResponseHepatotoxicityIn VitroIndividualLeadMAPK7 geneMalignant NeoplasmsMaximum Tolerated DoseMethodsMolecular ChaperonesMolecular ConformationN-terminalPatientsPeripheral Nervous System DiseasesPharmaceutical ChemistryPharmaceutical PreparationsProcessPropertyProtein IsoformsProteinsReportingScheduleSideSignal TransductionStructureToxic effectValidationantitumor agentbasecancer therapycell growthclinical candidatecomputer studiesdrug developmentin vivoinhibitor/antagonistmyelinationneuropeptide Ynovel strategiesprotein degradationprotein foldingresearch clinical testingside effectsmall molecule inhibitor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The 90 kDa heat shock proteins (Hsp90) are responsible for the maturation of approximately 200 client protein
substrates, most of which are associated with signaling cascades that regulate cellular growth and
proliferation. Therefore, Hsp90 inhibition provides a novel approach toward the treatment of cancer as
numerous signaling cascades can be derailed through inhibition of the Hsp90-dependent protein folding
process. In this application, we propose to develop selective inhibitors of the Hsp90 Isoforms, Grp94, Hsp90α,
and Hsp90β, using a structure-guided approach. In addition, we will perform side by side evaluation of these
compounds against pan-inhibitors both in vitro and in vivo to validate our approach. Together, these methods
will provide a new approach for selective inhibition of Hsp90 and will provide a new paradigm for anti-cancer
drug development.
期刊论文(19)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1021/acs.jmedchem.7b01608
发表时间:
2018-04-12
期刊:
Journal of medicinal chemistry
影响因子:
7.3
作者:
[Que NLS, Crowley VM, Duerfeldt AS, Zhao J, Kent CN, Blagg BSJ, Gewirth DT]
通讯作者:
Gewirth DT
DOI:
10.1016/j.jlr.2021.100114
发表时间:
2021
期刊:
Journal of lipid research
影响因子:
6.5
作者:
[Pipalia NH, Saad SZ, Subramanian K, Cross A, Al-Motawa A, Garg K, Blagg BSJ, Neckers L, Helquist P, Wiest O, Ory DS, Maxfield FR]
通讯作者:
Maxfield FR
DOI:
10.1002/anie.202015422
发表时间:
2021-05-03
期刊:
Angewandte Chemie (International ed. in English)
影响因子:
--
作者:
[Mishra SJ, Khandelwal A, Banerjee M, Balch M, Peng S, Davis RE, Merfeld T, Munthali V, Deng J, Matts RL, Blagg BSJ]
通讯作者:
Blagg BSJ
DOI:
10.2174/1568009619666191202101330
发表时间:
2020
期刊:
Current cancer drug targets
影响因子:
3
作者:
[Sanchez J, Carter TR, Cohen MS, Blagg BSJ]
通讯作者:
Blagg BSJ
The discovery and development of binimetinib for the treatment of melanoma.
双米替尼用于治疗黑色素瘤的发现和发展。
DOI:
10.1080/17460441.2020.1746265
发表时间:
2020-07
期刊:
Expert opinion on drug discovery
影响因子:
6.3
作者:
[Tran B, Cohen MS]
通讯作者:
Cohen MS
共 16 条
Engineering the Next Generation of Safer Hsp90 Inhibitors
-
批准号:10587304
-
项目类别:
-
资助金额:$46.33万
-
财政年份:2023
-
负责人:Brian S J Blagg
-
依托单位:
Development and Evaluation of Purine and Coumarin Based Hsp90 Inhibitors
-
批准号:9514012
-
项目类别:
-
资助金额:$35.33万
-
财政年份:2018
-
负责人:Brian S J Blagg
-
依托单位:
Hsp90B in Bladder Cancer
-
批准号:9922232
-
项目类别:
-
资助金额:$35.17万
-
财政年份:2018
-
负责人:Brian S J Blagg
-
依托单位:
Optimization and Investigation of Cruentaren A analogs
-
批准号:9454428
-
项目类别:
-
资助金额:$34.25万
-
财政年份:2018
-
负责人:Brian S J Blagg
-
依托单位:
Optimization and Investigation of Cruentaren A analogs
-
批准号:9902368
-
项目类别:
-
资助金额:$35.3万
-
财政年份:2018
-
负责人:Brian S J Blagg
-
依托单位:
Development and Evaluation of Purine and Coumarin Based Hsp90 Inhibitors
-
批准号:9600723
-
项目类别:
-
资助金额:$44.39万
-
财政年份:2018
-
负责人:Brian S J Blagg
-
依托单位:
Optimization and Investigation of Cruentaren A analogs
-
批准号:10078544
-
项目类别:
-
资助金额:$35.3万
-
财政年份:2018
-
负责人:Brian S J Blagg
-
依托单位:
New paradigms for Hsp90 inhibition
-
批准号:9762054
-
项目类别:
-
资助金额:$34.35万
-
财政年份:2017
-
负责人:Brian S J Blagg
-
依托单位:
New paradigms for Hsp90 inhibition
-
批准号:9379940
-
项目类别:
-
资助金额:$36.66万
-
财政年份:2017
-
负责人:Brian S J Blagg
-
依托单位:
Grp94-selective inhibitors to treat heredity glaucoma
-
批准号:8928624
-
项目类别:
-
资助金额:$41.23万
-
财政年份:2014
-
负责人:Brian S J Blagg
-
依托单位:
Grp94-selective inhibitors to treat heredity glaucoma
-
批准号:8785724
-
项目类别:
-
资助金额:$43.54万
-
财政年份:2014
-
负责人:Brian S J Blagg
-
依托单位:
Chaperone therapeutics for the treatment of DPN
-
批准号:8636503
-
项目类别:
-
资助金额:$31.44万
-
财政年份:2012
-
负责人:Brian S J Blagg
-
依托单位:
Chaperone therapeutics for the treatment of DPN
-
批准号:8297562
-
项目类别:
-
资助金额:$31.82万
-
财政年份:2012
-
负责人:Brian S J Blagg
-
依托单位:
Chaperone therapeutics for the treatment of DPN
-
批准号:8413041
-
项目类别:
-
资助金额:$30.68万
-
财政年份:2012
-
负责人:Brian S J Blagg
-
依托单位:
Development of Hsp90 inhibitors for the treatment of cancer
-
批准号:8456077
-
项目类别:
-
资助金额:$29.3万
-
财政年份:2012
-
负责人:Brian S J Blagg
-
依托单位:
Development of Hsp90 inhibitors for the treatment of cancer
-
批准号:8627592
-
项目类别:
-
资助金额:$30.29万
-
财政年份:2012
-
负责人:Brian S J Blagg
-
依托单位:
Chaperone therapeutics for the treatment of DPN
-
批准号:8824587
-
项目类别:
-
资助金额:$31.73万
-
财政年份:2012
-
负责人:Brian S J Blagg
-
依托单位:
COBRE: U KS: P1: ID OF HSP90 COCHAPERONES, IMMUNOPHILINS & PROTEINS
-
批准号:7720669
-
项目类别:
-
资助金额:$2.61万
-
财政年份:2008
-
负责人:Brian S J Blagg
-
依托单位:
HSP90 Inhibitors
-
批准号:8184864
-
项目类别:
-
资助金额:$24.43万
-
财政年份:2006
-
负责人:Brian S J Blagg
-
依托单位:
Hsp90 Inhibitors
-
批准号:7038182
-
项目类别:
-
资助金额:$25.32万
-
财政年份:2006
-
负责人:Brian S J Blagg
-
依托单位:
海外基金